PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19804631-0 2009 Thermochemotherapy effect of nanosized As2O3/Fe3O4 complex on experimental mouse tumors and its influence on the expression of CD44v6, VEGF-C and MMP-9. Arsenic Trioxide 39-44 vascular endothelial growth factor C Mus musculus 135-141 19804631-8 2009 In addition, thermochemotherapy with the nanosized As2O3/Fe3O4 complex significantly inhibited the expression of CD44v6, VEGF-C, and MMP-9 mRNA (p < 0.05 for each). Arsenic Trioxide 51-56 vascular endothelial growth factor C Mus musculus 121-127 19804631-9 2009 CONCLUSION: As2O3/Fe3O4 complex combined with MFH had is a promising technique for the minimally invasive elimination of solid tumors and may be have anticancerometastasic effect by inhibiting the expression of CD44v6, VEGF-C, and MMP-9. Arsenic Trioxide 12-17 vascular endothelial growth factor C Mus musculus 219-225 19099632-0 2008 [Effect of arsenic trioxide on vascular endothelial growth factor-C and its receptor (VEGFR-3) in nude mice with gastric cancer]. Arsenic Trioxide 11-27 vascular endothelial growth factor C Mus musculus 31-67 19099632-8 2008 It is concluded that As2O3 can inhibit expression of VEGF-C and VEGFR-3 of human gastric cancer xenografts in nude mice, which suggests that As2O3 may inhibit the lymphangiogenesis by suppressing the expression of VEGF-C and VEGFR-3. Arsenic Trioxide 141-146 vascular endothelial growth factor C Mus musculus 214-220 19099632-1 2008 This study was aimed to investigate the effect of arsenic trioxide (As2O3) on expression of vascular endothelial growth factor-C (VEGF-C) and its receptor VEGFR-3 in gastric cancer in order to clarify the role of As2O3 in lymphangiogenesis and metastasis of tumor. Arsenic Trioxide 50-66 vascular endothelial growth factor C Mus musculus 92-128 19099632-1 2008 This study was aimed to investigate the effect of arsenic trioxide (As2O3) on expression of vascular endothelial growth factor-C (VEGF-C) and its receptor VEGFR-3 in gastric cancer in order to clarify the role of As2O3 in lymphangiogenesis and metastasis of tumor. Arsenic Trioxide 50-66 vascular endothelial growth factor C Mus musculus 130-136 19099632-1 2008 This study was aimed to investigate the effect of arsenic trioxide (As2O3) on expression of vascular endothelial growth factor-C (VEGF-C) and its receptor VEGFR-3 in gastric cancer in order to clarify the role of As2O3 in lymphangiogenesis and metastasis of tumor. Arsenic Trioxide 68-73 vascular endothelial growth factor C Mus musculus 92-128 19099632-1 2008 This study was aimed to investigate the effect of arsenic trioxide (As2O3) on expression of vascular endothelial growth factor-C (VEGF-C) and its receptor VEGFR-3 in gastric cancer in order to clarify the role of As2O3 in lymphangiogenesis and metastasis of tumor. Arsenic Trioxide 68-73 vascular endothelial growth factor C Mus musculus 130-136 19099632-1 2008 This study was aimed to investigate the effect of arsenic trioxide (As2O3) on expression of vascular endothelial growth factor-C (VEGF-C) and its receptor VEGFR-3 in gastric cancer in order to clarify the role of As2O3 in lymphangiogenesis and metastasis of tumor. Arsenic Trioxide 213-218 vascular endothelial growth factor C Mus musculus 130-136 19099632-8 2008 It is concluded that As2O3 can inhibit expression of VEGF-C and VEGFR-3 of human gastric cancer xenografts in nude mice, which suggests that As2O3 may inhibit the lymphangiogenesis by suppressing the expression of VEGF-C and VEGFR-3. Arsenic Trioxide 21-26 vascular endothelial growth factor C Mus musculus 214-220 of surfactant protein A and mannose-binding protein from mannose > galactose to the converse. Mannose 155-162 surfactant protein A1 Homo sapiens 101-121 7782337-5 1995 The indicated mutations have previously been shown to change the carbohydrate binding specificity of surfactant protein A and mannose-binding protein from mannose > galactose to the converse. Galactose 168-177 surfactant protein A1 Homo sapiens 101-121 7782337-6 1995 rSP-D expressed in mammalian cells was essentially identical to native rat SP-D in its lipid and carbohydrate binding properties. Carbohydrates 97-109 surfactant protein D Rattus norvegicus 0-5 7782337-8 1995 The efficiency of SP-DE321Q,N323D binding to PI liposome was approximately 50% of that of rSP-D in the presence of 5 mM Ca2+, but equivalent at 20 mM Ca2+. TFF2 protein, human 18-20 surfactant protein D Rattus norvegicus 90-95 7782337-9 1995 Carbohydrates competed for SP-D binding to PI such that maltose > galactose for rSP-D, and the order was reversed for SP-DE321Q,N323D. Carbohydrates 0-13 surfactant protein D Rattus norvegicus 27-31 7782337-9 1995 Carbohydrates competed for SP-D binding to PI such that maltose > galactose for rSP-D, and the order was reversed for SP-DE321Q,N323D. Carbohydrates 0-13 surfactant protein D Rattus norvegicus 83-88 7782337-9 1995 Carbohydrates competed for SP-D binding to PI such that maltose > galactose for rSP-D, and the order was reversed for SP-DE321Q,N323D. Maltose 56-63 surfactant protein D Rattus norvegicus 27-31 7782337-9 1995 Carbohydrates competed for SP-D binding to PI such that maltose > galactose for rSP-D, and the order was reversed for SP-DE321Q,N323D. Maltose 56-63 surfactant protein D Rattus norvegicus 83-88 7782337-9 1995 Carbohydrates competed for SP-D binding to PI such that maltose > galactose for rSP-D, and the order was reversed for SP-DE321Q,N323D. Galactose 69-78 surfactant protein D Rattus norvegicus 27-31 7782337-9 1995 Carbohydrates competed for SP-D binding to PI such that maltose > galactose for rSP-D, and the order was reversed for SP-DE321Q,N323D. Galactose 69-78 surfactant protein D Rattus norvegicus 83-88 7782337-12 1995 1) The carbohydrate binding specificity of SP-DE321Q,N323D was changed from a mannose-glucose type to a galactose type; 2) the GlcCer binding property of SP-D is closely related to its sugar binding activity; and 3) the PI binding activity is not completely dependent on its carbohydrate binding specificity. Carbohydrates 7-19 surfactant protein D Rattus norvegicus 43-47 7782337-12 1995 1) The carbohydrate binding specificity of SP-DE321Q,N323D was changed from a mannose-glucose type to a galactose type; 2) the GlcCer binding property of SP-D is closely related to its sugar binding activity; and 3) the PI binding activity is not completely dependent on its carbohydrate binding specificity. mannose-glucose 78-93 surfactant protein D Rattus norvegicus 43-47 7782337-12 1995 1) The carbohydrate binding specificity of SP-DE321Q,N323D was changed from a mannose-glucose type to a galactose type; 2) the GlcCer binding property of SP-D is closely related to its sugar binding activity; and 3) the PI binding activity is not completely dependent on its carbohydrate binding specificity. Galactose 104-113 surfactant protein D Rattus norvegicus 43-47 7782337-12 1995 1) The carbohydrate binding specificity of SP-DE321Q,N323D was changed from a mannose-glucose type to a galactose type; 2) the GlcCer binding property of SP-D is closely related to its sugar binding activity; and 3) the PI binding activity is not completely dependent on its carbohydrate binding specificity. Glucosylceramides 127-133 surfactant protein D Rattus norvegicus 43-47 7782337-12 1995 1) The carbohydrate binding specificity of SP-DE321Q,N323D was changed from a mannose-glucose type to a galactose type; 2) the GlcCer binding property of SP-D is closely related to its sugar binding activity; and 3) the PI binding activity is not completely dependent on its carbohydrate binding specificity. Sugars 185-190 surfactant protein D Rattus norvegicus 43-47 7782337-12 1995 1) The carbohydrate binding specificity of SP-DE321Q,N323D was changed from a mannose-glucose type to a galactose type; 2) the GlcCer binding property of SP-D is closely related to its sugar binding activity; and 3) the PI binding activity is not completely dependent on its carbohydrate binding specificity. Carbohydrates 275-287 surfactant protein D Rattus norvegicus 43-47